Automated coverage for Merck & Co., Inc.. Sector: Health Care. Pending deep research for full thesis.
FDA Breakthrough Therapy designation for calderasib (MK-1084) + KEYTRUDA in first-line KRAS G12C-mutant NSCLC (2026-05-29); catalyst/monitoring status hygiene
Fianlimab + Libtayo Phase 3 Harmony Melanoma trial failed primary endpoint vs Keytruda (pembrolizumab) head-to-head
Positioning skews toward near-term upside